荣昌生物制药（烟台）股份有限公司

Activities and Presentations

Select Year

●2026
●2024
●2023
●2022

Select Clear

First-Line Disitamab Vedotin, Tislelizumab, and S-1 in HER2-Overexpressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Phase II Trial PDF
2026 EULAR：Efficacy and safety of Telitacicept in patients with Sjögren’s disease PDF
RCTS_2026_ASCO:Disitamab vedotin (RC48), Tislelizumab, and S-1 as first-line therapy for HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Updated survival and exploratory biomarker results from the RCTS trial PDF
Abstract TPS4245_2026 ASCO:Efficacy and safety of disitamab vedotin (DV) combined with trastuzumab, and tislelizumab versus chemotherapy (CAPOX) combined with trastuzumab ± pembrolizumab for patients with first-line HER2-high advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA): a randomized controlled phase 3 trial PDF
Abstract LBA4026_2026 ASCO：Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (Chemo)/trastuzumab (Tra) for first-line (1L) HER2- expressing locally advanced or metastatic (la/m) gastric cancer (GC): Updated results from the RC48-C027 trial PDF
Abstract 598_2026 ASCO：Efficacy and safety of neoadjuvant disitamab vedotin (DV) in combination with toripalimab (Tor) and concurrent/sequential chemotherapy (chemo) in patients with HR-negative, HER2-low breast cancer: A randomized multicenter phase 2 study PDF
RemeGen 2025 Annual Results PDF
Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with HER2-expressing muscle-invasive bladder cancer (MIBC) in the phase II RC48-C017 trial: updated results PDF
JP Morgan Healthcare Conference PDF
A Phase 1/2 Study of RC148 (PD-1/VEGF bispecific antibody) monotherapy or in combination with docetaxel for the treatment of first- or second-line locally advanced or metastatic non-small-cell lung cancer (la/mNSCLC) without actionable genomic alterations (AGA) PDF

< 1/3 >